Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride.

Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Abstract Text:

T Lewander,

Remoxipride is a selective dopamine D2 antagonist with virtually no activity on other transmitter receptors. It antagonizes dopamine agonists within a wide dose range in animals when it does not cause sedation or akinesia. Clinical studies with remoxipride have demonstrated antipsychotic efficacy apparently equal to classical neuroleptics in short- and long-term treatment of schizophrenia. Remoxipride has a low extrapyramidal syndrome (EPS) profile, and it is generally well tolerated. In clinical practice remoxipride has been reported to differ from classical neuroleptics with regard to subjective side effects. On switching to remoxipride, patients report improvement in cognitive, conative, affective and emotional functions. In many cases the reports are supported by family members and/or caregivers. Although anecdotal, such reports are in line with the low EPS profile of remoxipride and its weak sedative properties. It may indicate that remoxipride does not elicit the neuroleptic-induced deficit syndrome, commonly experienced with classical neuroleptics, or that remoxipride improves the deficit syndrome (or primary negative symptoms) of schizophrenia. These and other hypotheses need to be confirmed by formal clinical studies.

Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Publishing Authors By Initials

T Lewander,

For similar behavioral disciplines and activities: schizophrenic psychology research abstracts see: behavioral disciplines and activities: schizophrenic psychology research

PUBMED ID PMID:

MEDLINE DATE:

Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Journal Published:

PUBLICATION TYPE: Review

Journal: Acta psychiatrica Scandinavica. Supplementum

VOLUME: 380

Page Numbers: 64-7

Journal Abbreviation:

ISSN: 0065-1591

DAY: 15

MONTH: 02

YEAR: 1994

Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370365

Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Keywords Mesh Terms:

KEYWORDS: Schizophrenic Psychology

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Information

Substance Name: Remoxipride

Registry Number: 80125-14-0

Grant and Affiliation Information for Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride.

AFFILIATION: Astra Arcus AB, CNS R & D, Södertälje, Sweden.

Country: DENMARK

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Psychiatr Scand Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride Related Publications

• Neuroleptics and the neuroleptic-induced deficit syndrome.
• Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride.
• Pharmacodynamic and pharmacokinetic studies in rats of S-8-(2-Furyl)- and R-8-phenyl-2-(di-n-propylamino) tetralin, two novel 5-HT1A receptor agonists in-vitro with different properties in-vivo.